Goldman Sachs Downgrades Vertex (VRTX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Vertex Pharma (VRTX) Sees Red-to-Green Reversal Following EPS
April 28, 2016 10:27 AM EDTVertex Pharma (NASDAQ: VRTX) reverse sharply off morning lows following earning after the close, which were seen as lackluster.
Shares are currently up 1% after opening down 3.9%.
... MoreVertex (VRTX) PT, Estimates Cut at Baird
April 28, 2016 7:45 AM EDTBaird analyst Brian Skorney lowered his price target on Vertex (NASDAQ: VRTX) to $128.00 (from $144.00) and Orkambi estimates on weak qua but maintained an Outperform rating.
Skorney commented, "Orkambi sales came in well below expectations that had already been revised significantly downwards over the last... More
Vertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance
April 27, 2016 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.09, $0.20 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $398.1 million versus the consensus estimate of $439.36 million.
First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI® (lumacaftor/ivacaftor) and $171 million for KALYDECO®... More
